Only time will reveal CER's true definition, and determine the full effects of a CER-based system
Personalized medicines often come to market without much safety information. Small populations mean less data. Genzyme, for example, received FDA approval for Cerezyme, to treat Gaucher disease, based on a pivotal trial with only 30 patients.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva